RAPT Therapeutics Inc

RAPT Therapeutics — Investor Presentation (January 2025)

25 slides from RAPT Therapeutics's investor presentation, Jan 13, 2025

  1. Slide 1: January 2025 Corporate Presentation

    January 2025 Corporate Presentation

  2. Slide 2: Disclaimer

    Disclaimer Statements in this Presentation that are not statements of historical fact are forward-looking statements. Such forward-looking statements include, without limitation, statements regarding our research and clinical development plans; current and future drug candidates; the development of

  3. Slide 3: RAPT is Developing Transformative Therapies for High-Value Inflammatory Diseases

    RAPT is Developing Transformative Therapies for High-Value Inflammatory Diseases RPT904 is a half-life extended omalizumab (Xolair®) “bio-better” with potential to transform the treatment of Food Allergy (FA) and Chronic Spontaneous Urticaria (CSU) Potential best-in-class profile with less frequent

  4. Slide 4: RAPT Therapeutics Pipeline

    INFLAMMATION PROGRAMS DISCOVERY PRECLINICAL PHASE 1 PHASE 2 PHASE 3 RPT904 Anti-IgE mAb Next Gen. CCR4 antagonist RAPT Therapeutics Pipeline # RAPT has licensed ex-China rights including US, Europe, and Japan; Jemincare retains China, Taiwan, Hong Kong and Macau * Clinical collaboration with Merck *

  5. Slide 5: Potential to Transform the Treatment of Food Allergy and CSU

    Potential to Transform the Treatment of Food Allergy and CSU RPT904

  6. Slide 6: Omalizumab is an Emerging Blockbuster in Large and Growing Food Allergy Market

    Omalizumab is an Emerging Blockbuster in Large and Growing Food Allergy Market There are ~17M FA patients in the US1 → ~50% have had severe reactions2 → ~3.4M ER visits/year2 Treatment dominated by inconvenient treatments: food avoidance and single allergen desensitization (i.e. OIT) Omalizumab is t

  7. Slide 7: Strong Reception to RPT904's Profile from Prescribers and Payers

    Strong Reception to RPT904’s Profile from Prescribers and Payers Despite omalizumab’s early success, payers and prescribers would welcome a longer-acting treatment like RPT904 for increased compliance and convenience* * Based on primary market research n=140 prescribers, Oct 2024 and n=45 payers, No

  8. Slide 8: CSU Offers Additional Commercial Upside

    CSU Offers Additional Commercial Upside CSU affects >1M patients in the US1 Antihistamines are first treatment step, but ~400k patients not controlled on antihistamines2 Omalizumab is only approved biologic for CSU after failure of antihistamines RPT904 positioned to be preferred choice in front-lin

  9. Slide 9: A Potential Best-in-Class Omalizumab Bio-Better mAb

    A Potential Best-in-Class Omalizumab Bio-Better mAb RPT904

  10. Slide 10: RPT904: Minimally Altered to Optimize Dosing Frequency While Targeting Clinically Validated Epitope

    RPT904: Minimally Altered to Optimize Dosing Frequency While Targeting Clinically Validated Epitope Omalizumab as starting point Retains clinically validated epitope YTE mutation: half-life extension Additional conservative improvements Affinity maturation: ~4-fold affinity over omalizumab PTM site

  11. Slide 11: Potential Best-In-Class anti-IgE Option for Food Allergy

    Potential Best-In-Class anti-IgE Option for Food Allergy Potential Attributes RPT904 Omalizumab Clinically validated epitope Effective on multiple allergens Convenience of Q8W/Q12W dosing Access to High IgE and/or Weight Patients Simplified Dosing Table

  12. Slide 12: Phase 1 Healthy Volunteer Data and Dose Estimations

    Phase 1 Healthy Volunteer Data and Dose Estimations RPT904

  13. Slide 13: Jemincare Phase 1 Healthy Volunteer Study Design

    Jemincare Phase 1 Healthy Volunteer Study Design: Double-blind, placebo-controlled single ascending dose study of RPT904 (JYB1904) and an omalizumab comparator in healthy Chinese subjects Objectives: Tolerability, safety, immunogenicity, PK and PD Route of administration: subcutaneous (SC) injection

  14. Slide 14: Jemincare Phase 1 Trial Shows Longer Half-Life and Superior IgE Reduction

    Jemincare Phase 1 of RPT904 Trial Shows Longer Half-Life and Superior IgE Reduction Compared to Omalizumab At 150 mg, half life for RPT904 was 60 Days vs. 26 days for omalizumab Superior free IgE reduction relative to omalizumab PD comparisons of absolute free-IgE levels to other trials not possible

  15. Slide 15: Omalizumab FA Dosing Table is Complex and Excludes High IgE/Weight Patients

    Omalizumab FA Dosing Table is Complex and Excludes High IgE/Weight Patients Approved food allergy table for omalizumab based on well-established PK/PD models and target free IgE levels 8 dose strengths 75-600 mg; 2 frequencies Q2 or Q4W (13 different regimens) ~30% of FA patients excluded from label

  16. Slide 16: Pharmacodynamic Simulations Support Q12W Dosing In Most Patients

    Pharmacodynamic Simulations Support Q12W Dosing In Most Patients Omalizumab 150 mg Q4W is approved dose; achieves target IgE levels Q8W would not achieve target levels RPT904 at 150 mg Q12W predicted to achieve target IgE Levels Perform simulations at 150, 300 and 600 mg Q12W across table *Target fr

  17. Slide 17: Phase 2 Trial Designs

    Phase 2 Trial Designs RPT904

  18. Slide 18: Proposed Phase 2b Randomized Double-Blind Placebo-Controlled Study in Food Allergy

    RPT904 Q12W regimen (N=30) Primary Endpoint: Prespecified threshold by oral food challenge N=75 (2:2:1 Q12W, Q8W regimens and placebo) US/European clinical sites ~18 months from FPI to topline data Proposed Phase 2b Randomized Double-Blind Placebo-Controlled Study of RPT904 Monotherapy in Food Aller

  19. Slide 19: Phase 2b FA Simplified Dosing Regimens Cover Entire Omalizumab Dosing Table

    Phase 2b FA Simplified Dosing Regimens Cover Entire Omalizumab Dosing Table Randomization Illustrative simplified dosing table based on baseline IgE and weight 3 dose strengths compared to omalizumab’s 8 dose strengths Plan is to include patients currently excluded from omalizumab label Additional P

  20. Slide 20: Jemincare Asthma and CSU Clinical Development Plan

    Jemincare Asthma and CSU Clinical Development Plan 2025 2026 2027 2028 2029 2030 Phase 2a Asthma Data Phase 2 CSU Data Phase III Asthma Start Phase III Asthma Data Phase III CSU Start Phase III CSU Data Phase 2a Asthma Patients with mod-severe asthma (N=60) 3 dose levels of JYB1904 Q8W vs. omalizuma

  21. Slide 21: RPT904 Anticipated Milestones

    RPT904 Anticipated Milestones 1H 2025 2H 2025 1H 2026 2H 2026 1H 2027 2H 2027 FA Phase 2b Start (US/Europe) FA Phase 2b Data CSU Phase 2 or 3 Start (US/Europe) Asthma Data (China) CSU Data (China) PK/PD HV Data PK/PD Atopic Data Jemincare RAPT

  22. Slide 22: Next Generation CCR4 Antagonist

    First-in-Class Oral Th2 Inhibitor for Inflammatory Diseases Next Generation CCR4 Antagonist

  23. Slide 23: First-in-Class Oral Th2 Inhibitor for Inflammatory Diseases

    First-in-Class Oral Th2 Inhibitor for Inflammatory Diseases Highly potent and selective once-daily oral CCR4 antagonist designed to safely reduce Th2-inflammation Next generation CCR4 antagonist with improved potency and liver safety margins Data from zelnecirnon Phase 2 trials in asthma and atopic

  24. Slide 24: RAPT is Developing Transformative Therapies for High-Value Inflammatory Diseases

    RAPT is Developing Transformative Therapies for High-Value Inflammatory Diseases RPT904 is a half-life extended omalizumab (Xolair®) “bio-better” with potential to transform the treatment of Food Allergy (FA) and Chronic Spontaneous Urticaria (CSU) Potential best-in-class profile with less frequent

  25. Slide 25: Thank You

    Thank You

RAPT Therapeutics — Investor Presentation (January 2025) on 6ix